IceCure Medical (ICCM) completed the first patient treatment in its ChoICE post-marketing study evaluating ProSense cryoablation for low-risk breast cancer.The patient was enrolled and treated at West Cancer Center & Research Institute in Germantown, Tennessee, by Dr. Richard E. Fine. Cryoablation destroys tumors by freezing. The study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites and generate real-world data within ProSense's FDA-cleared indication. IceCure expects participating sites to operate as both study centers and commercial sites, offering treatment to eligible patients outside the study.

Reported Tuesday, Oct 20 - 7:57am EDT (TheFly subscription required to read more.)

IceCure Medical (ICCM) enrolled the first two patients at U.S. sites in its ChoICE post-marketing study of ProSense breast cancer cryoablation. The study evaluates local treatment of low-risk breast cancer using freezing to destroy tumors. The patients were enrolled at West Cancer Center & Research Institute in Germantown, Tennessee, and Adventist Health Glendale in California.ChoICE is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites, generating real-world data within ProSense's FDA-cleared indication. Both initial sites received institutional review board approval and signed site agreements before becoming eligible to enroll patients in August 2026. Legacy Health's Good Samaritan Medical Center in Portland, Oregon, joined the network earlier this month. IceCure expects participating centers to also operate as commercial sites, treating eligible patients outside the study.

At EUSOBI 2026, IceCure Medical presented impressive clinical data for ProSense® cryoablation, demonstrating strong physician engagement and successful outcomes.

IceCure Medical (Nasdaq: ICCM) presented ProSense breast cancer cryoablation clinical data at the European Society of Breast Imaging’s 2026 annual meeting.Presentations reported 12-month objective response rates, a measure of tumor response, of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone. Cryoablation destroys tumors by freezing. The meeting took place in Maastricht, the Netherlands.ProSense featured in two scientific sessions, including findings on elderly breast cancer patients ineligible for surgery. IceCure hosted two clinical workshops, each attracting nearly 70 participants. Two posters by ProSense users addressed one-year outcomes for breast lesions in Romania and imaging to predict tissue response after breast cryoablation.

Lg — 499 €

IceCure Medical has added Legacy Health in Portland, OR, as a clinical site for its ongoing ProSense® ChoICE Study on low-risk breast cancer treatments.

IceCure Medical has received regulatory approval from China's National Medical Products Administration to market its ProSense® cryoablation system, marking a significant milestone for the company.

CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it...

Reported Thursday, Sep 10 - 8:01am EDT (TheFly subscription required to read more.)

The NMPA approved ProSense as a Class III medical device with associated cryoprobes, allowing IceCure to market it under the registration.

IceCure Medical has signed a unique distribution agreement with Scovas Medical in the Netherlands to enhance the availability of its ProSense® cryoablation systems, targeting breast cancer treatment.

Agreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the highest complete ablation rate among evaluated thermal ablation technologies CAESAREA,...

IceCure Medical (Nasdaq: ICCM) signed an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands, covering breast cancer and interventional oncology. Scovas will initially act as exclusive distributor, with a view to negotiating a longer-term agreement subject to both parties.According to IceCure, the deal supports market development and clinical education in a country with strong interventional radiology expertise. The Netherlands-hosted, independent multicenter randomized THERMAC trial has advanced to Phase III focusing on cryoablation, after earlier data showed ProSense® achieved the highest complete ablation rate among evaluated thermal ablation techniques, with a 94% success rate, 0% complication rate and 100% treatment tolerance without general anesthesia.

Reported Thursday, Aug 20 - 8:21am EDT (TheFly subscription required to read more.)

IceCure Medical announces new findings that reinforce the clinical importance of cryoablation in breast cancer treatment de-escalation strategies, marking a significant advancement in patient care.

New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph...

ProSense has FDA marketing authorization for selected women 70 and older; a second paper discusses axillary nodes and curative or palliative use.

IceCure Medical Ltd. reports a 45% increase in revenue for the first half of 2026, driven by strong adoption of its innovative cryoablation technology, ProSense.

IceCure Medical (NASDAQ: ICCM) reported first-half 2026 revenue of $1.8 million, up about 45% from $1.25 million in 2025, driven by higher ProSense® system and disposable probe sales. Gross profit rose to $548,000. The active U.S. commercial installed base grew approximately 70% following FDA clearance, reflecting increased physician adoption and procedure volumes.Net loss widened to $8.8 million versus $7.0 million a year earlier, as research and development, sales and marketing, and general and administrative expenses all increased. IceCure strengthened its balance sheet through multiple financings, ending June 30, 2026 with about $12.0 million in cash and cash equivalents and shareholders’ equity of $11.9 million. The Company continued to invest in its U.S. sales force and advanced its FDA-approved post-marketing CHoICE Study, while clinical visibility was supported by guideline inclusion, peer-reviewed publications, and five-year kidney cancer data.

Israel defeating cancer, again. This Israeli technology can destroy tumors by freezing them, without surgery or radiation. IceCure Medical’s ProSense system uses cryoablation. A tiny probe delivers extreme cold (liquid nitrogen) to precisely freeze and kill cancerous tumors in https://t.co/MCEacMKEXv